Short answer
Tectonic Therapeutic, Inc. (TECX) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Third-quarter results for the period ended September 30, 2026 announced.
Tectonic Therapeutic, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Third-quarter results for the period ended September 30, 2026 announced
- General business update accompanying the quarterly financial release
- Exhibit 99.1 contains the detailed results and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 net loss $21.3M, or $1.08 per share, versus $19.0M and $1.02 in Q3 2025
- Cash $234.7M, including approximately $22.3M ATM proceeds, supports runway into Q1 2029 under current assumptions
- TX2100 Phase 1a showed no serious or severe treatment-emergent adverse events, enabling HHT Phase 1b by year-end 2026
- TX45 APEX Phase 2 topline results expected by end-January 2027, the next major clinical catalyst
- TX45 ALPINE Phase 2a first patient dosed, with interim topline results expected in the second half of 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tectonic Therapeutic, Inc. 8-K filings
Get the next TECX 8-K as it lands
Follow TECX for push alerts, or ask the research agent what this filing means.